PinnyPeptide

ARA-290 (Cibinetide) vs TB-500

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ARA-290 (Cibinetide)

Healing & Recovery

Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects.

Peptide B

TB-500

Healing & Recovery

Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity.

Typical vial

8 mg

Typical dose

2,000-8,000 mcg

Half-life

~2 minutes (plasma); longer functional duration via receptor binding

FDA status

Not FDA approved. In clinical development by Araim Pharmaceu…

Typical vial

5 mg

Typical dose

2000-5000 mcg

Half-life

~6-8 hours

FDA status

Not FDA approved for human use.

ARA-290 (Cibinetide) effects

  • Activates the innate repair receptor (IRR / EpoR-βcR heterodimer)
  • Reduces tissue inflammation in injury models
  • Promotes axonal regeneration in small-fiber neuropathy
  • Does NOT raise hemoglobin or platelet count
  • Tissue-protective in ischemia-reperfusion models

TB-500 effects

  • Promotes wound healing and tissue repair
  • Reduces inflammation and fibrosis
  • Stimulates new blood vessel growth
  • Supports cardiac repair after ischemic injury
  • Enhances cell migration through actin upregulation

ARA-290 (Cibinetide) side effects

  • Generally well-tolerated in clinical trials
  • Injection-site reactions (mild)
  • No erythropoietic effects (deliberate design)
  • Long-term safety with chronic dosing still being characterized

TB-500 side effects

  • Injection site irritation
  • Temporary head rush or lightheadedness
  • Mild lethargy
  • Headache

ARA-290 (Cibinetide) dosing ranges

Small-fiber neuropathy / nerve healing

2-8 mg · Once daily (SubQ) · 4-12 weeks per cycle

General tissue protection research

1-4 mg · Daily or alternate-day · Per research protocol

TB-500 dosing ranges

Acute injury healing

2000-5000 mcg · Twice weekly · 4-6 weeks

Maintenance and recovery

2000 mcg · Once weekly · 4-8 weeks

Full ARA-290 (Cibinetide) guide → Full TB-500 guide →

ARA-290 (Cibinetide) vs TB-500 — common questions

What is the difference between ARA-290 (Cibinetide) and TB-500?

ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. TB-500: Synthetic fragment of Thymosin Beta-4 with potent tissue repair activity. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.

Can you stack ARA-290 (Cibinetide) and TB-500?

Stacking ARA-290 (Cibinetide) with TB-500 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ARA-290 (Cibinetide) or TB-500?

ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. TB-500 is typically dosed: Twice weekly for Acute injury healing; Once weekly for Maintenance and recovery.

Are ARA-290 (Cibinetide) and TB-500 FDA approved?

ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. TB-500: Not FDA approved for human use.

Related peptide comparisons

ara-290 vs b7-33ara-290 vs bpc-157ara-290 vs kpvara-290 vs tb-500-frag-17-23ara-290 vs vipb7-33 vs tb-500

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free